Compare · ABBV vs PBH
ABBV vs PBH
Side-by-side comparison of AbbVie Inc. (ABBV) and Prestige Consumer Healthcare Inc. (PBH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and PBH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $406.38B, about 188.7x PBH ($2.15B).
- Over the past year, ABBV is up 27.4% and PBH is down 45.3% - ABBV leads by 72.7 points.
- ABBV has been more active in the news (14 items in the past 4 weeks vs 3 for PBH).
- ABBV has more recent analyst coverage (25 ratings vs 12 for PBH).
- Company
- AbbVie Inc.
- Prestige Consumer Healthcare Inc.
- Price
- $234.09+1.77%
- $46.11+1.47%
- Market cap
- $406.38B
- $2.15B
- 1M return
- +9.07%
- -4.24%
- 1Y return
- +27.40%
- -45.34%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2012
- 2005
- News (4w)
- 14
- 3
- Recent ratings
- 25
- 12
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye allergies/redness relief, Compound W wart removals, Debrox ear wax removals, DenTek for PEG oral care, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
- AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
- AbbVie Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
- AbbVie Declares Quarterly Dividend
- Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
- Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
- FDA Approval for SKYRIZI issued to ABBVIE INC
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest PBH
- Prestige Consumer Healthcare Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits
- Prestige Consumer Healthcare Inc Completes Acquisition of Breathe Right®
- Prestige Consumer Healthcare Inc. to Participate in the Oppenheimer Annual Consumer Growth and E-Commerce Conference
- SEC Form 10-K filed by Prestige Consumer Healthcare Inc.
- Amendment: CFO & COO Sacco Christine covered exercise/tax liability with 1,091 shares, decreasing direct ownership by 2% to 57,374 units (SEC Form 4)
- Prestige Consumer downgraded by Oppenheimer
- Prestige Consumer Healthcare Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Prestige Consumer Healthcare Inc. Reports Fiscal 2026 Results, Announces Acquisition of LaCorium Health
- Senior VP Operations Zerillo Jeffrey sold $18,350 worth of shares (351 units at $52.28), decreasing direct ownership by 0.83% to 41,810 units (SEC Form 4)
- Senior VP Operations Zerillo Jeffrey sold $16,580 worth of shares (305 units at $54.36) and covered exercise/tax liability with 351 shares, decreasing direct ownership by 2% to 42,161 units (SEC Form 4)